Literature DB >> 18469326

Implications of clinical trial design on sample size requirements.

Andrew C Leon1.   

Abstract

The primary goal in designing a randomized controlled clinical trial (RCT) is to minimize bias in the estimate of treatment effect. Randomized group assignment, double-blinded assessments, and control or comparison groups reduce the risk of bias. The design must also provide sufficient statistical power to detect a clinically meaningful treatment effect and maintain a nominal level of type I error. An attempt to integrate neurocognitive science into an RCT poses additional challenges. Two particularly relevant aspects of such a design often receive insufficient attention in an RCT. Multiple outcomes inflate type I error, and an unreliable assessment process introduces bias and reduces statistical power. Here we describe how both unreliability and multiple outcomes can increase the study costs and duration and reduce the feasibility of the study. The objective of this article is to consider strategies that overcome the problems of unreliability and multiplicity.

Entities:  

Mesh:

Year:  2008        PMID: 18469326      PMCID: PMC2632464          DOI: 10.1093/schbul/sbn035

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  15 in total

1.  Guidance for human somatic cell therapy and gene therapy.

Authors: 
Journal:  Hum Gene Ther       Date:  2001-02-10       Impact factor: 5.695

2.  Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.

Authors:  Andrew C Leon
Journal:  J Clin Psychiatry       Date:  2004-11       Impact factor: 4.384

Review 3.  Size of treatment effects and their importance to clinical research and practice.

Authors:  Helena Chmura Kraemer; David J Kupfer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

4.  A comparison of multiplicity adjustment strategies for correlated binary endpoints.

Authors:  Andrew C Leon; Moonseong Heo
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

5.  Statistical power of multiplicity adjustment strategies for correlated binary endpoints.

Authors:  Andrew C Leon; Moonseong Heo; Jedediah J Teres; Toshihiko Morikawa
Journal:  Stat Med       Date:  2007-04-15       Impact factor: 2.373

6.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

7.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

8.  The analysis of multiple endpoints in clinical trials.

Authors:  S J Pocock; N L Geller; A A Tsiatis
Journal:  Biometrics       Date:  1987-09       Impact factor: 2.571

9.  More reliable outcome measures can reduce sample size requirements.

Authors:  A C Leon; P M Marzuk; L Portera
Journal:  Arch Gen Psychiatry       Date:  1995-10

10.  Intrinsic motivation in schizophrenia: relationships to cognitive function, depression, anxiety, and personality.

Authors:  Deanna M Barch; Naomi Yodkovik; Hannah Sypher-Locke; Melissa Hanewinkel
Journal:  J Abnorm Psychol       Date:  2008-11
View more
  14 in total

1.  Test-retest reliability and validity of a frustration paradigm and irritability measures.

Authors:  Wan-Ling Tseng; Elizabeth Moroney; Laura Machlin; Roxann Roberson-Nay; John M Hettema; Dever Carney; Joel Stoddard; Kenneth A Towbin; Daniel S Pine; Ellen Leibenluft; Melissa A Brotman
Journal:  J Affect Disord       Date:  2017-01-23       Impact factor: 4.839

2.  Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.

Authors:  Eric J Lenze; David Dixon; Petra Nowotny; Francis E Lotrich; Peter M Doré; Bruce G Pollock; Anthony L Hinrichs; Meryl A Butters
Journal:  Int J Neuropsychopharmacol       Date:  2012-04-17       Impact factor: 5.176

3.  The interactive computer interview for mania.

Authors:  Noreen A Reilly-Harrington; Daniel DeBonis; Andrew C Leon; Louisa Sylvia; Roy Perlis; Daniel Lewis; Gary S Sachs
Journal:  Bipolar Disord       Date:  2010-08       Impact factor: 6.744

4.  Feasibility of Pairing Behavioral Activation With Exercise for Women With Type 2 Diabetes and Depression: The Get It Study Pilot Randomized Controlled Trial.

Authors:  Kristin L Schneider; Emily Panza; Barbara Handschin; Yunsheng Ma; Andrew M Busch; Molly E Waring; Bradley M Appelhans; Matthew C Whited; Jacey Keeney; Daniel Kern; Mihaela Blendea; Ira Ockene; Sherry L Pagoto
Journal:  Behav Ther       Date:  2015-10-31

5.  Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Authors:  Andrew C Leon; Lori L Davis
Journal:  J Trauma Stress       Date:  2009-12

6.  Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.

Authors:  Deanna M Barch; Cameron S Carter; Amy Arnsten; Robert W Buchanan; Jonathan D Cohen; Mark Geyer; Michael F Green; John H Krystal; Keith Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

7.  The effects of meditation on individuals facing loneliness: a scoping review.

Authors:  Gurleen K Saini; Saud B Haseeb; Zhala Taghi-Zada; Jeremy Y Ng
Journal:  BMC Psychol       Date:  2021-05-22

Review 8.  Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Authors:  Richard S E Keefe; Robert W Buchanan; Stephen R Marder; Nina R Schooler; Ashish Dugar; Milana Zivkov; Michelle Stewart
Journal:  Schizophr Bull       Date:  2011-11-22       Impact factor: 9.306

Review 9.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 10.  Blinding in Clinical Trials: Seeing the Big Picture.

Authors:  Thomas F Monaghan; Christina W Agudelo; Syed N Rahman; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.